Asterand | GenomeWeb

Asterand

The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.

The company will provide oncology specimens and associated clinical data to the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium.

5AM Solutions will develop software that will allow Asterand to electronically link multiple biorepositories and identify, annotate, and distribute biospecimen data internally and with collaborators.

The contract to supply biospecimens for the Cancer Genome Atlas project could reach a total value of $24 million.

BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.

The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.

BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.

New Product Watch

Premium

Affymetrix, Febit, Asterand, ImaGenes

BMS will continue to use Asterand's tissue-based drug-discovery products and services for up to three years.

The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.